Journal of Surgical Research
Volume 148, Issue 2 , Pages 143-151 , August 2008

Elevated Fas Expression Is Related to Increased Apoptosis of Circulating CD8+ T Cell in Patients With Gastric Cancer

Received 7 April 2007

References 

  1. Garrido F, Cabrera T, Concha A, et al. Natural history of HLA expression during tumor development. Immunol Today. 1993;14:491
  2. Tanaka Y, Tevethia SS. In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones. J Immunol. 1988;140:4348
  3. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med. 1993;177:265
  4. Tada T, Ohzeki S, Utsumi K, et al. Transforming growth factor-beta-induced inhibition of T cell function (Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state). J Immunol. 1991;146:1077
  5. Matsuda M, Salazar F, Petersson M, et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and down-regulates HLA class I expression. J Exp Med. 1994;180:2371
  6. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993;53:5613
  7. Zea AH, Curti BD, Longo DL, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res. 1995;1:1327
  8. Kono K, Ressing ME, Brandt RM, et al. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res. 1996;2:1825
  9. Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993;53:5610
  10. Lai P, Rabinowich H, Crowley-Nowick PA, et al. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res. 1996;2:161
  11. Reichert TE, Day R, Wagner EM, et al. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 1998;58:5344
  12. Hoffmann TK, Muller-Berghaus J, Ferris RL, et al. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res. 2002;8:1787
  13. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6:1755
  14. Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002;8:2553
  15. Reichert TE, Strauss L, Wagner EM, et al. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res. 2002;8:3137
  16. Bauernhofer T, Kuss I, Henderson B, et al. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol. 2003;33:119
  17. Gastman BR, Atarshi Y, Reichert TE, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 1999;59:5356
  18. Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med. 1999;5:938
  19. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 2002;8:793
  20. Xu T, Shu CT, Purdom E, Dang D, et al. Microarray analysis reveals differences in gene expression of circulating CD8(+) T cells in melanoma patients and healthy donors. Cancer Res. 2004;64:3661
  21. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science. 1996;274:1363
  22. O'Connell J, O'Sullivan GC, Collins JK, et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996;184:1075
  23. Siegel RM, Martin DA, Zheng L, et al. Death-effector filaments: novel cytoplasmic structures that recruit caspases and trigger apoptosis. J Cell Biol. 1998;141:1243
  24. Boon T, Cerottini JC, Van den Eynde B, et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12:337
  25. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: Molecular definition and implications. Mol Med Today. 1997;3:342
  26. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immuno-editing: From immunosurveillance to tumor escape. Nat Immunol. 2002;3:991
  27. Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol. 2003;111:S677
  28. Ries L, Eisner M, Kosary C. SEER Cancer Statistics Review, 1975–2000. Bethesda, MD: National Cancer Institute; 2003;
  29. Takahashi A, Kono K, Amemiya H, et al. Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apoptosis and down-regulation of TCR zeta molecules in patients with gastric cancer. Clin Cancer Res. 2001;7:74
  30. Ichihara F, Kono K, Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003;9:4404
  31. Osaki T, Saito H, Yoshikawa T, et al. Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res. 2007;13:382
  32. Krammer PH. CD95's deadly mission in the immune system. Nature. 2000;407:789
  33. Stuart PM, Griffith TS, Usui N, et al. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest. 1997;99:396
  34. Bechmann I, Mor G, Nilsen J, et al. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia. 1999;27:62
  35. Orlinick JR, Elkon KB, Chao MV. Separate domains of the human Fas ligand dictate self-association and receptor binding. J Biol Chem. 1997;272:32221
  36. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777
  37. Mizutani Y, Hongo F, Sato N, et al. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer. 2001;92:287
  38. Nagao M, Nakajima Y, Hisanaga M, et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo?. Hepatology. 1999;30:413
  39. Song E, Chen J, Ouyang N, Su F, et al. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer. 2001;85:1047

PII: S0022-4804(07)00472-6

doi: 10.1016/j.jss.2007.07.011

Journal of Surgical Research
Volume 148, Issue 2 , Pages 143-151 , August 2008

Article Tools

* Image Usage & Resolution